-
Mashup Score: 2Ublituximab Reduced Annualized Relapse Rate and Disability Progression in Multiple Sclerosis - Practical Neurology - 4 year(s) ago
In the phase 3 ULTIMATE trials (NCT03277261 and NCT03277248), ublituximab (UTX)(TG Therapeutics, New York, NY) decreased (ARR) and disability progress
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Expanded Disability Status Scale Available on Digital Platform - Practical Neurology - 5 year(s) ago
The proprietary platform (eCOA Pathway; VeraSci, Durham, NC) has been expanded to fully integrate the Expanded Disability Status Scale (EDSS) assessme
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet-
Expanded Disability Status Scale Available on Digital Platform #PracticalNeurology #MS #multipleschlerosis #EDSS #eCOAPathway @_VeraSci https://t.co/QDTHG7pkjK
-
#Ublituximab Reduced Annualized Relapse Rate and Disability Progression in Multiple Sclerosis #neurology #multipleschlerosis #MS #PracticalNeurology https://t.co/6anlpbMA4G